James W. Purcell MS, PhD

James Purcell is a Principal Research Scientist within the Oncology Discovery organization of AbbVie, based out of Redwood City California. His current research focuses on developing novel antibody drug conjugates (ADCs) in particular ADC target biology, pharmacology and investigating new drug/linker technologies. He has helped to progress antibody-based biologics from the bench into Phase 1 development as part of AbbVie (e.g., LRRC15-ADC, ABBV-085) and during his time at Abbott/Facet Biotech (e.g., TweakR mAb, epratuzumab). The prior experience involved the preclinical and translational evaluation of the first small molecule kinesin spindle protein inhibitor (Ispinesib) that progressed into clinical trials (Cytokinetics/GSK). James holds a Ph.D. from the Center for Cancer Research and Cell Biology at Queens University, U.K., as well as an M.S. in Molecular Medicine and B.S. in Biochemistry from Trinity College, Ireland.